Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database
Frontiers in Pharmacology · 09.01.2025 · 15
DOI: 10.3389/fphar.2024.1509310 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 09.01.2025. Verfasst von Peiyang Cao und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Objective
This study aims to analyze the adverse drug events (ADEs) associated with tolvaptan in the Food and Drug Administration Adverse Event Reporting System database from the fourth quarter of 2009 to the second quarter of 2024.
Methods
After standardizing the data, various signal detection techniques, including Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network, and Multi-Item Gamma Poisson Shrinker, were employed for analysis.
Results
Among the 7,486 ADE reports where tolvaptan was the primary suspected drug, a total of 196 preferred terms were identified, spanning 24 different system organ classes. Specifically, hepatobiliary disorders, renal and urinary disorders, and metabolic and nutritional disorders were found to be characteristic adverse reactions associated with tolvaptan. Additionally, uncommon but notable ADE signals were observed, such as renal cyst rupture, renal cyst infection, polycystic liver disease, and renal cyst hemorrhage. These several ADEs have not been referred to in the previous literature. Notably, strong ADE signals were detected for decreased urine osmolality [n = 5, ROR 149.74, PRR 149.7, IC (Information Component) 7.13, EBGM (Empirical Bayes Geometric Mean) 139.79], osmotic demyelination syndrome (n = 38, ROR 128.47, PRR 128.25, IC 6.92, EBGM 120.91), and pulmonary-related tumors such as bronchial metastatic carcinoma, bronchial carcinoma, metastatic small cell lung carcinoma, and small cell lung carcinoma. In the concomitant medication analysis of 7,486 suspected adverse drug reaction reports related to tolvaptan, the top three drugs most commonly used in combination with tolvaptan were furosemide, spironolactone, and amlodipine.
Conclusion
While tolvaptan provides therapeutic benefits, it poses a risk of significant adverse reactions. Clinicians should closely monitor the occurrence of events related to hepatobiliary disorders, renal and urinary disorders, metabolic and nutritional disorders, as well as benign, malignant, and indeterminate tumors during its clinical use.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Nephrology, The Fourth Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China.
- Department of Cardiology, Affiliated Changshu Hospital of Nantong University, Changshu, China.
Zitieren
APA
Cao, P., Wang, Q., Wang, Y., Qiao, Q., & Yan, L. (2025). Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database. Frontiers in Pharmacology, 15. https://doi.org/10.3389/fphar.2024.1509310
Vancouver
Cao P, Wang Q, Wang Y, Qiao Q, Yan L. Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database. Frontiers in Pharmacology. 2025;15. doi:10.3389/fphar.2024.1509310
BibTeX
@article{Cao2025,
author = {Cao, Peiyang and Wang, Qian and Wang, Yan and Qiao, Qing and Yan, Liyuan},
title = {Safety assessment of tolvaptan: real-world adverse event analysis using the FAERS database},
journal = {Frontiers in Pharmacology},
year = {2025},
volume = {15},
doi = {10.3389/fphar.2024.1509310}
}
EUVIMED